Timosaponin A3CAS# 41059-79-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 41059-79-4 | SDF | Download SDF |
PubChem ID | 71306914 | Appearance | White powder |
Formula | C39H64O13 | M.Wt | 740.92 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Synonyms | Anemarsaponin A 3; Filiferin B; Xilingsaponin A; Zhi-mu saponin | ||
Solubility | DMSO : 50 mg/mL (67.48 mM; Need ultrasonic) | ||
Chemical Name | (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1R,2S,4S,6R,7S,8R,9S,12S,13S,16S,18R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | ||
SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)C)C)OC1 | ||
Standard InChIKey | MMTWXUQMLQGAPC-HRSJJQGESA-N | ||
Standard InChI | InChI=1S/C39H64O13/c1-18-7-12-39(47-17-18)19(2)28-25(52-39)14-24-22-6-5-20-13-21(8-10-37(20,3)23(22)9-11-38(24,28)4)48-36-34(32(45)30(43)27(16-41)50-36)51-35-33(46)31(44)29(42)26(15-40)49-35/h18-36,40-46H,5-17H2,1-4H3/t18?,19-,20+,21-,22+,23-,24-,25-,26+,27+,28-,29+,30-,31-,32-,33+,34+,35-,36+,37-,38-,39+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters, it has selectively cytotoxic for cancer versus normal cells. Timosaponin A3 can inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV2 microglia cells, it has the therapeutic potential for various neurodegenerative diseases caused by inflammation. Timosaponin A3 also has application for reducing blood sugar and treating type-B diabete. |
Targets | ROS | HO-1 | TNF-α | NF-kB | p38MAPK |
In vitro | Timosaponin A3 is a steroidal saponin from Anemarrhena asphodeloides that has a selective cytotoxic activity towards cancer cells.[Reference: WebLink]Cancer Res., 2009, 69:18-22.We have identified Timosaponin A3 (TspA3) as an active compound from BN108 that is responsible for the selective cytotoxicity for the whole extract. TspA3 is a steroidal saponin whose activity against cancer cells remained unexplored until now. |
In vivo | Timosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters.[Pubmed: 25087997]Acta Pharmacol Sin. 2014 Sep;35(9):1188-98.To investigate the mechanisms underlying the hepatotoxicity of Timosaponin A3 (TA3), a steroidal saponin from Anemarrhena asphodeloides, in rats. Application of timosaponin A3 for preparing medicine for treating No.2 type diabetes mellitus[Reference: WebLink]CN20021060151, 2002.An application of anemarrhena saponin AIII extracted from anemarrhena rhizome in preparing the medicines for reducing blood sugar and treating type-B diabetes is disclosed. Application of Timosaponin A3 for preparing medicine for treating No.2 type diabetes mellitus |
Cell Research | Timosaponin A3 and Sarsasapogenin inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV-2 microglia cells.[Reference: WebLink]Planta Med., 2008, 74(9):965-965.Anemarrhena asphodeloides Bunge (AA, family Liliaceae), which contains steroidal saponins, such as Timosaponin A3(TA3) and sarsasapogenin (SS), has been used as an antipyretic, anti-inflammatory, anti-diabetic, and antidepressant in traditional Chinese medicine.
|
Timosaponin A3 Dilution Calculator
Timosaponin A3 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.3497 mL | 6.7484 mL | 13.4967 mL | 26.9935 mL | 33.7418 mL |
5 mM | 0.2699 mL | 1.3497 mL | 2.6993 mL | 5.3987 mL | 6.7484 mL |
10 mM | 0.135 mL | 0.6748 mL | 1.3497 mL | 2.6993 mL | 3.3742 mL |
50 mM | 0.027 mL | 0.135 mL | 0.2699 mL | 0.5399 mL | 0.6748 mL |
100 mM | 0.0135 mL | 0.0675 mL | 0.135 mL | 0.2699 mL | 0.3374 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sirtinol
Catalog No.:BCC2224
CAS No.:410536-97-9
- Palovarotene
Catalog No.:BCC4185
CAS No.:410528-02-8
- H-D-Ala-OBzl.TosOH
Catalog No.:BCC2850
CAS No.:41036-32-2
- Desacetylcinobufotalin
Catalog No.:BCC8166
CAS No.:4099-30-3
- Medioresinol
Catalog No.:BCN5462
CAS No.:40957-99-1
- Glycitein
Catalog No.:BCN5896
CAS No.:40957-83-3
- Taxiresinol
Catalog No.:BCN4637
CAS No.:40951-69-7
- VU0152100
Catalog No.:BCC4053
CAS No.:409351-28-6
- JNJ 16259685
Catalog No.:BCC7332
CAS No.:409345-29-5
- 3,4-Dimethoxycinnamyl alcohol
Catalog No.:BCN6499
CAS No.:40918-90-9
- Sinoacutine
Catalog No.:BCN5461
CAS No.:4090-18-0
- H-Tyr-OEt.HCl
Catalog No.:BCC3125
CAS No.:4089-07-0
- Lipiferolide
Catalog No.:BCN5463
CAS No.:41059-80-7
- Neobavaisoflavone
Catalog No.:BCN3194
CAS No.:41060-15-5
- Skullcapflavone I
Catalog No.:BCN5464
CAS No.:41060-16-6
- Steviolbioside
Catalog No.:BCN6800
CAS No.:41093-60-1
- Memantine hydrochloride
Catalog No.:BCC9018
CAS No.:41100-52-1
- Platyphyllonol
Catalog No.:BCN5465
CAS No.:41137-85-3
- Hirsutanonol
Catalog No.:BCN5466
CAS No.:41137-86-4
- Hirsutenone
Catalog No.:BCN5467
CAS No.:41137-87-5
- Boc-Phe(4-F)-OH
Catalog No.:BCC3219
CAS No.:41153-30-4
- CMPD-1
Catalog No.:BCC7274
CAS No.:41179-33-3
- erythro-Guaiacylglycerol beta-sinapyl ether 7-O-glucoside
Catalog No.:BCN7348
CAS No.:412029-03-9
- Pseudolarolide F
Catalog No.:BCN6428
CAS No.:412321-91-6
Timosaponin A3 induces hepatotoxicity in rats through inducing oxidative stress and down-regulating bile acid transporters.[Pubmed:25087997]
Acta Pharmacol Sin. 2014 Sep;35(9):1188-98.
AIM: To investigate the mechanisms underlying the hepatotoxicity of Timosaponin A3 (TA3), a steroidal saponin from Anemarrhena asphodeloides, in rats. METHODS: Male SD rats were administered TA3 (100 mg.kg(-1).d(-1), po) for 14 d, and the blood and bile samples were collected after the final administration. The viability of a sandwich configuration of cultured rat hepatocytes (SCRHs) was assessed using WST-1. Accumulation and biliary excretion index (BEI) of d8-TCA in SCRHs were determined with LC-MS/MS. RT-PCR and Western blot were used to analyze the expression of relevant genes and proteins. ROS and ATP levels, and mitochondrial membrane potential (MMP) were measured. F-actin cytoskeletal integrity was assessed under confocal microscopy. RESULTS: TA3 administration in rats significantly elevated the total bile acid in serum, and decreased bile acid (BA) component concentrations in bile. TA3 inhibited the viability of the SCRHs with an IC50 value of 15.21+/-1.73 mumol/L. Treatment of the SCRHs with TA3 (1-10 mumol/L) for 2 and 24 h dose-dependently decreased the accumulation and BEI of d8-TCA. The TA3 treatment dose-dependently decreased the expression of BA transporters Ntcp, Bsep and Mrp2, and BA biosynthesis related Cyp7a1 in hepatocytes. Furthermore, the TA3 treatment dose-dependently increased ROS generation and HO-1 expression, decreased the ATP level and MMP, and disrupted F-actin in the SCRHs. NAC (5 mmol/L) significantly ameliorated TA3-induced effects in the SCRHs, whereas mangiferin (10-200 mug/mL) almost blocked TA3-induced ROS generation. CONCLUSION: TA3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters. Mangiferin, an active component in Anemarrhena, may protect hepatocytes from TA3-induced hepatotoxicity.